8. ハンチントン病 Huntington disease Clinical trials / Disease details
臨床試験数 : 229 / 薬物数 : 193 - (DrugBank : 60) / 標的遺伝子数 : 84 - 標的パスウェイ数 : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04713982 (ClinicalTrials.gov) | November 19, 2021 | 6/1/2021 | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | Huntington Disease | Drug: Deutetrabenazine | Vanderbilt University Medical Center | Teva Branded Pharmaceutical Products R&D, Inc. | Recruiting | 18 Years | N/A | All | 30 | Phase 2/Phase 3 | United States |
| 2 | NCT04301726 (ClinicalTrials.gov) | September 1, 2020 | 13/2/2020 | Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD | Efficacy of Deutetrabenazine in Huntington's Disease Patients With Dysphagia: A Randomised, Placebo-controlled Pilot Study | Huntington Disease | Drug: Deutetrabenazine Oral Tablet [Austedo];Drug: Placebo oral tablet | Fundacion Huntington Puerto Rico | NULL | Not yet recruiting | 21 Years | N/A | All | 48 | Phase 1 | NULL |
| 3 | NCT04071639 (ClinicalTrials.gov) | March 12, 2020 | 26/8/2019 | Symptomatic Therapy for Patients With Huntington's Disease | Non-randomized Control Clinical Trial to Evaluate the Efficacy and Safety of Symptomatic Drug Therapy for Mild to Moderate Huntington's Disease Patients | Huntington Disease | Drug: Haloperidol 2Mg Tab;Drug: Risperidone 1Mg Tab;Drug: Zoloft 50Mg Tablet;Drug: Idebenone;Drug: Deutetrabenazine Oral Tablet [Austedo] | Second Affiliated Hospital, School of Medicine, Zhejiang University | NULL | Recruiting | N/A | N/A | All | 60 | Phase 1 | China |